Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, indicating strong corporate execution and potential for profitability in the near future [1][3]. Group 1: Transaction Details - Cyprium entered into a definitive asset purchase agreement to sell its PRV for gross proceeds of $205 million upon closing [1]. - The PRV was issued following the FDA approval of ZYCUBO on January 12, 2026, which was developed by Cyprium and is intended for the treatment of Menkes disease [2]. - Cyprium will receive tiered royalties on net sales of ZYCUBO and up to $129 million in development and sales milestones from Sentynl Therapeutics [2]. Group 2: Company Achievements - The approval of ZYCUBO is a significant milestone for patients with Menkes disease, showcasing Cyprium's ability to execute value-generating transactions [3]. - Fortress has received three FDA approvals in the last 15 months for its products, including Emrosi™, UNLOXCYT™, and ZYCUBO, positioning the company for potential profitability this year [3]. - Cyprium is advancing AAV-ATP7A Gene Therapy toward clinical development, which aims to provide additional treatment options for Menkes disease [3][4]. Group 3: Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related copper metabolism disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed prescription products and multiple development programs across various therapeutic areas [5][6].